NCT02711683View on ClinicalTrials.gov

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

CompletedOBSERVATIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Alzheimer's Disease
Interventions
DRUG

DL-3-n-butylphthalide

the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.

DRUG

Donepezil

the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.

Trial Locations (1)

710061

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT02711683 - DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil | Biotech Hunter | Biotech Hunter